Teachers Advisors LLC Boosts Holdings in The Medicines Company (MDCO)

Teachers Advisors LLC raised its holdings in shares of The Medicines Company (NASDAQ:MDCO) by 1.2% during the third quarter, according to its most recent filing with the SEC. The firm owned 257,633 shares of the company’s stock after purchasing an additional 3,164 shares during the period. Teachers Advisors LLC owned 0.35% of The Medicines worth $7,706,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. SG Americas Securities LLC grew its position in shares of The Medicines by 144.4% in the 2nd quarter. SG Americas Securities LLC now owns 12,462 shares of the company’s stock worth $457,000 after buying an additional 7,362 shares during the last quarter. Schwab Charles Investment Management Inc. grew its position in shares of The Medicines by 2.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 343,474 shares of the company’s stock worth $12,606,000 after buying an additional 6,830 shares during the last quarter. Legal & General Group Plc grew its position in shares of The Medicines by 2.4% in the 2nd quarter. Legal & General Group Plc now owns 141,516 shares of the company’s stock worth $5,101,000 after buying an additional 3,334 shares during the last quarter. PNC Financial Services Group Inc. grew its position in shares of The Medicines by 24.2% in the 2nd quarter. PNC Financial Services Group Inc. now owns 13,095 shares of the company’s stock worth $481,000 after buying an additional 2,550 shares during the last quarter. Finally, OppenheimerFunds Inc. grew its position in shares of The Medicines by 0.3% in the 2nd quarter. OppenheimerFunds Inc. now owns 707,160 shares of the company’s stock worth $25,953,000 after buying an additional 1,777 shares during the last quarter.

MDCO stock opened at $19.74 on Monday. The company has a market capitalization of $1.46 billion, a P/E ratio of -2.35 and a beta of 1.06. The company has a quick ratio of 2.40, a current ratio of 2.41 and a debt-to-equity ratio of 31.23. The Medicines Company has a 52 week low of $16.69 and a 52 week high of $41.57.

The Medicines (NASDAQ:MDCO) last released its earnings results on Thursday, November 8th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.13). The Medicines had a negative return on equity of 1,477.75% and a negative net margin of 668.93%. The company had revenue of ($3.30) million during the quarter, compared to analyst estimates of $1.88 million. During the same quarter last year, the business earned ($1.19) earnings per share. The firm’s revenue for the quarter was down 141.8% on a year-over-year basis. As a group, equities research analysts forecast that The Medicines Company will post -2.91 EPS for the current fiscal year.

In other The Medicines news, CEO Mark Timney acquired 2,926 shares of the firm’s stock in a transaction on Friday, December 21st. The stock was acquired at an average cost of $17.90 per share, for a total transaction of $52,375.40. Following the purchase, the chief executive officer now owns 29,789 shares in the company, valued at approximately $533,223.10. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Christopher T. Cox acquired 113,500 shares of the firm’s stock in a transaction on Thursday, December 20th. The shares were acquired at an average price of $17.70 per share, with a total value of $2,008,950.00. Following the completion of the purchase, the executive vice president now owns 60,308 shares in the company, valued at approximately $1,067,451.60. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 1,052,589 shares of company stock valued at $20,865,236. Company insiders own 10.29% of the company’s stock.

A number of analysts recently commented on MDCO shares. Cowen set a $46.00 target price on shares of The Medicines and gave the stock a “buy” rating in a research note on Sunday, November 11th. Zacks Investment Research upgraded shares of The Medicines from a “sell” rating to a “hold” rating in a research note on Friday, December 7th. BidaskClub upgraded shares of The Medicines from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 22nd. Oppenheimer set a $50.00 target price on shares of The Medicines and gave the stock a “buy” rating in a research note on Friday, November 9th. Finally, ValuEngine cut shares of The Medicines from a “buy” rating to a “hold” rating in a research note on Monday, September 24th. One analyst has rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $49.67.

WARNING: This article was reported by WKRB News and is owned by of WKRB News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.wkrb13.com/2019/01/14/teachers-advisors-llc-boosts-holdings-in-the-medicines-company-mdco.html.

The Medicines Company Profile

The Medicines Company, a biopharmaceutical company, provides medicines to treat acute and intensive care patients. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention in the United States.

See Also: Capital gains and your 401(k) or IRA

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

Receive News & Ratings for The Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply